american academy of allergy asthma & immunology Alyatec Regeneron



The results of the clinical study conducted by ALYATEC for Regeneron Pharmaceuticals will be presented in the next congress of the American Academy of Allergy, Asthma and Immunology (AAAAI). The congress will be held virtually from February 26 to March 1, 2021.

Also, results from a collaboration between ALYATEC and the Brugmann University Hospital Center in Brussels will be the subject of a poster presentation during this event.


Here is the information related to the two projects:

  • Oral Abstract Session (2/27/2021, 5:10 pm – 6:25 pm) – Abstract #504: A Single-Dose of REGN1908-1909 Reduced Bronchoconstriction in Cat-Allergic Subjects with Mild Asthma for up to 3 months following a controlled cat allergen challenge: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study.
  • Poster Presentation – Abstract #164: EEC exposure to mite in allergic asthma induces an increase of function and recruitment molecules on blood Treg.


Congress website:



ALYATEC REGENERON cat asthma  ALYATEC AAAAI Université Libre de Bruxelles CHU Brugmann